ReviewOpen forum infectious diseases2020
The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent
Review in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.BMC infectious diseases · 2022Trial
- A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.Gastroenterology · 2021Trial
- Mechanisms and Therapeutic Potential of Nutritional Immunity.Pathogens (Basel, Switzerland) · 2026Review
- Gut-Adipose Tissue Axis and Metabolic Health.Current issues in molecular biology · 2025Review
- Mechanisms ofFrontiers in cellular and infection microbiology · 2025Review
- Transfer of modified gut viromes improves symptoms associated with metabolic syndrome in obese male mice.Nature communications · 2024Article
- Fecal microbiota transplantation in a patient with chronic diarrhea and primary and secondary immunodeficiency (common variable immunodeficiency and splenectomy).Frontiers in cellular and infection microbiology · 2024Article
- Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool.The Journal of infectious diseases · 2023Article
- Unveiling the hidden world of gut health: Exploring cutting-edge research through visualizing randomized controlled trials on the gut microbiota.World journal of clinical cases · 2023Article
- SER-109: An Oral Investigational Microbiome Therapeutic for Patients with RecurrentAntibiotics (Basel, Switzerland) · 2022Review
- Bioengineered 3D Tissue Model of Intestine Epithelium with Oxygen Gradients to Sustain Human Gut Microbiome.Advanced healthcare materials · 2022Article
- Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics.Nature reviews. Microbiology · 2022Review
- Next-generation sequencing: insights to advance clinical investigations of the microbiome.The Journal of clinical investigation · 2022Review
- Validation of Two Commercial Multiplex Real-Time PCR Assays for Detection of SARS-CoV-2 in Stool Donors for Fecal Microbiota Transplantation.Microorganisms · 2022Article
- Frontiers in antibiotic alternatives forWorld journal of gastroenterology · 2021Article
- Silent hypoxia in COVID-19: a gut microbiota connection.Current opinion in physiology · 2021Review
- Host genetic control of gut microbiome composition.Mammalian genome : official journal of the International Mammalian Genome Society · 2021Review
- Antibiotics at the crossroads - Do we have any therapeutic alternatives to control the emergence and spread of antimicrobial resistance?Journal of education and health promotion · 2021Review
- Fecal microbiota transplants: A review of emerging clinical data on applications, efficacy, and risks (2015-2020).Qatar medical journal · 2021Article
- Safety of fecal microbiota transplantation forTherapeutic advances in gastroenterology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The leading risk factor for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.